Takeda recalls Natpara but warns patients not to abruptly stop treatment
Takedaís been looking for a buyer for Natpara to provide some debt relief, but it has just run into some complicating circumstances. It is having to recall the drug from the market, a move it says may be very challenging for patients.
Takeda today announced it was voluntarily recalling all doses of the injected drug for hypoparathyroidism in the U.S. because there was a chance of small rubber particles shedding into the injectors.
But the Japanese drugmaker was adamant that patients mustnít stop the treatment abruptly because of the danger of a sudden drop in blood calcium levels. Instead, patients must have their doctor replace the drug with supplements and carefully monitor their calcium levels with blood tests.